The newly developed antibody 6H4 fragments (Fabs) specific to A? oligomers, encapsulated in the polymeric nanomicelles (PMs), were peripherally administrated to AD model mouse for 10 weeks. In mice that were administered anti-A?O 6H4 Fabs in the PMs, various toxic A? species (A? oligomers, A?42s, N3pE A?s, A?s with toxic conformer) and the presence of A? plaques with dense cores in the brain were significantly reduced. Additionally, suppression of the progression of pathological processes of AD was supported by the prevention of cognitive-behavioral decline in the spatial memory tests.
CREDIT: Department of Neurology and Neurological Science, TMDU
Researchers led by Tokyo Medical and Dental University (TMDU) find that antibody fragments encapsulated in nanomicelles cross the blood–brain barrier and reduce the levels of toxic A? species in the brain of an Alzheimer’s disease model mouse
Sometimes the best things in life come by chance, when we happen to be in the right place at the right time. Now, researchers from Japan have found a way to ensure that new medications are delivered to the right place in the body and at the right timepoint in disease progression, so that they have the best effect.
In a study published recently in the Journal of Nanobiotechnology, researchers led by Tokyo Medical and Dental University (TMDU) have revealed that a novel delivery system delivers treatment to where it is needed most in a mouse model of Alzheimer’s disease (AD).
AD is a common neurodegenerative disease that causes dementia. It is characterized by the accumulation of a protein called amyloid ? (A?) in the brain, and a number of different toxic forms of A? have been identified that impair brain function, notably A? oligomers (A?Os).
“Multiple clinical trials have attempted to use an anti-A? antibody to treat AD, but the results have been unsatisfactory,” says lead author of the study Akiko Amano. “One potential explanation for this is that the blood–brain barrier (BBB) prevents most full-length antibodies from entering the brain.”
To address this challenge, the researchers previously developed glucosylated (sugar-linked) polymeric nanomicelles (PMs), which are tiny, hollow balls that could successfully cross the BBB via transcytosis in mouse brain capillary endothelial cells; this process was mediated by glucose-transporter-1 and induced by an increase in blood glucose levels after the mice experienced fasting conditions. In this study, Takanori Yokota and colleagues filled PMs with fragments of an anti-A?O antibody, injected them into a mouse model of AD, and assessed the effects on the brain and on behavior.
“The results were very clear,” explains senior author Nobuo Sanjo. “Administration of anti-A?O antibody fragments through PMs significantly reduced the amounts of various toxic A? species. In addition, the A? plaques that did form were smaller and less dense than those seen in untreated mice.”
Next, the researchers analyzed the behavior of the mice and found that the mice treated with the antibody fragment-filled PMs had better learning and spatial memory than untreated mice. “Our findings suggest that delivering sufficient levels of antibodies to the brain using PMs can reduce toxic A? species and slow AD progression in mice,” says Amano.
Given that the failure of anti-A? antibodies to improve cognitive function in human clinical trials was likely because of an insufficient supply of the antibodies in the brain, PM-encapsulated antibody fragments could represent an effective way to prevent AD progression. In addition, new candidates for AD treatment that degrade toxic A?s and reduce their toxic effects could also be delivered to the brain using the same PM-based system.
Original Article: Transporting antibodies across the blood–brain barrier to treat Alzheimer’s disease
More from: Tokyo Medical and Dental University
The Latest Updates from Bing News
Go deeper with Bing News on:
Alzheimer’s disease
- Early Alzheimer’s disease could be diagnosed through eye exams, new study suggests
Alzheimer’s is a disease of the brain, usually diagnosed through MRI scans and a battery of other tests. Researchers, however, have found that the human eye can show early signals of this common form ...
- Alzheimer's first signs may appear in your eyes, study finds
Alzheimer's disease numbers increasing as baby boomers age, study says Alzheimer's disease numbers increasing as baby boomers age, study says 01:47 The eyes are more than a window to the soul — ...
- Volunteers needed in Alzheimer’s research that could spot disease decades before
WASHINGTON, D.C. (KXAN) — The number of Americans living with Alzheimer’s disease is expected to double in the next two decades, according to new findings by the Alzheimer’s Association. The report ...
- Alzheimer’s disease first signs may appear in your eyes, study finds
Research has been exploring how the eye may help in diagnosing Alzheimer’s disease before symptoms begin. The disease is well advanced by the time memory and behavior are affected. “Alzheimer’s ...
- North Texas-based nonprofit dedicated to fighting Alzheimer’s disease
In 1989, six women led the charge in creating A.W.A.R.E, or the Alzheimer’s Women’s Association for Resources and Education.
Go deeper with Bing News on:
PM-encapsulated antibody fragments
- Antibody fragment-nanoparticle therapeutic eradicates gastric cancer, shows research
The final product was a version of C' dots, armed with cancer-targeting antibody fragments and a large drug payload, all packed into a sub-7-nanometer, drug-immune conjugate therapy—a first of ...
- Method created to better remove protein causing Alzheimer’s
The researchers, primarily from Tokyo Medical and Dental University and the Innovation Center of Nanomedicine, encapsulated fragments of an antibody that can attach itself to the protein and ...
- Novel delivery system transports antibodies across the blood-brain barrier in Alzheimer’s mouse model
PM-encapsulated antibody fragments could represent an effective way to prevent AD progression. In addition, new candidates for AD treatment that degrade toxic Aβs and reduce their toxic effects ...
- Transporting antibodies across the blood–brain barrier to treat Alzheimer's disease
PM-encapsulated antibody fragments could represent an effective way to prevent AD progression. In addition, new candidates for AD treatment that degrade toxic Aβs and reduce their toxic effects ...
- Transporting antibodies across the blood–brain barrier to treat Alzheimer’s disease
PM-encapsulated antibody fragments could represent an effective way to prevent AD progression. In addition, new candidates for AD treatment that degrade toxic Aβs and reduce their toxic effects ...
